FDA Approves 0.5 mg Dose of Colchicine for High-Risk Patients with Inflammatory Risk

The FDA has granted approval for a 0.5 mg dose of colchicine for high-risk patients with atherosclerotic cardiovascular disease (CVD) or multiple cardiovascular risk factors who have residual inflammatory risk.